Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  European Journal of Pharmacology

• Publication date

  1997-08-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(97)01116-3PMID 9311667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children.

  1996cited by this paper
• Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors

  1995cited by this paper
• Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine?

  1995cited by this paper
• Efficacy of oral ketamine for providing sedation and analgesia to children requiring laceration repair

  1995cited by this paper
• Continuous subcutaneous administration of the N‐methyl‐D‐aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post‐herpetic neuralgia

  1995cited by this paper
• The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.

  1995cited by this paper
• Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.

  1995cited by this paper
• Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors.

  1995cited by this paper
• Excitatory amino acids and synaptic transmission

  1995cited by this paper
• Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence

  1993cited by this paper
• Excitatory amino acid receptors : design of agonists and antagonists

  1992cited by this paper
• Excitatory amino acids

  1992cited by this paper
• Pharmacological characterization of non‐NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro

  1992cited by this paper
• Metabolism of ketamine stereoisomers by human liver microsomes.

  1992cited by this paper
• Status of Ketamine in Anesthesiology.

  1992cited by this paper
• Identification of a novel NMDA receptor in rat cerebellum.

  1991cited by this paper
• The induction and maintenance of central sensitization is dependent on N‐methyl‐d‐aspartic acid receptor activation; implications for the treatment of post‐injury pain hypersensitivity states

  1991cited by this paper
• Activity‐Dependent Changes in Rat Ventral Horn Neurons in vitro; Summation of Prolonged Afferent Evoked Postsynaptic Depolarizations Produce a D‐2‐Amino‐5‐Phosphonovaleric Acid Sensitive Windup

  1990cited by this paper
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

  1990cited by this paper
• Ketamine: an update on the first twenty-five years of clinical experience

  1989cited by this paper
• The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system.

  1989cited by this paper
• Glutamate transmission and toxicity in Alzheimer's disease.

  1988cited by this paper
• Cooperative Modulation of [3H]MK‐801 Binding to the N‐Methyl‐d‐Aspartate Receptor‐Ion Channel Complex by l‐Glutamate, Glycine, and Polyamines

  1988cited by this paper
• 6,7-Dinitro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor.

  1988cited by this paper
• Excitatory amino acids in health and disease.

  1988cited by this paper
• Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation.

  1987cited by this paper
• Quantitative studies on some antagonists of N‐methyl D‐aspartate in slices of rat cerebral cortex

  1985cited by this paper
• Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro.

  1985cited by this paper
• Pharmacokinetics and analgesic effects of i.m. and oral ketamine.

  1982cited by this paper
• PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE

  1981cited by this paper
• Excitatory Amino Acid Receptors

  1980cited by this paper
• Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes.

  1979cited by this paper
• Specific [3H]phencyclidine binding in rat central nervous system.

  1979cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I

  1966cited by this paper

• Progress in the Application of Esketamine During the Perioperative Period.

  2026cites this paper
• PHARMACOLOGICAL ACTIVITY OF A NEW LIGAND BINDING AT THE HISTAMINE SITE OF THE NMDA RECEPTOR IN RODENTS.

  2026cites this paper
• De Novo Generation-Based Design of Potential Computational Hits Targeting the GluN1-GluN2A Receptor

  2026cites this paper
• The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine

  2025cites this paper
• Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

  2025cites this paper
• Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

  2025cites this paper
• Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor

  2025cites this paper
• Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits

  2025cites this paper
• L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice.

  2025cites this paper
• A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse

  2025cites this paper
• Subacute Effects of Ketamine on Neural Correlates of Reward Processing

  2025cites this paper
• Ketamine enantiomers and the gut microbiota: mechanisms, clinical implications, and future directions

  2025cites this paper
• Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review

  2025cites this paper
• Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis

  2025cites this paper
• (R)-Ketamine reduces alcohol intake and alcohol seeking induced by reconsolidation of alcohol-related memories in female Marchigian Sardinian alcohol-preferring rats.

  2025cites this paper
• Pharmacology of Commonly Used Sedative Agents.

  2025cites this paper
• Is there a risk of esketamine misuse in clinical practice?

  2025cites this paper
• High and Low Dose Ketamine in Post-Traumatic Stress Disorder

  2025cites this paper
• Recent advances in the synthesis of antidepressant derivatives: pharmacologic insights for mood disorders

  2024cites this paper
• Esketamine infusion as treatment for chronic endometriosis-associated pain? Study protocol for a randomized controlled trial (EASYlight-study)

  2024cites this paper
• Study on the antidepressant activity of (2R,6R; 2S,6S)-Hydroxynorketamine (HNK) and its derivatives

  2024cites this paper
• Ketamine Reduces Avoidance Responses During Re-Exposition to Aversive Stimulus: Comparison Between (S)-Isomer and Racemic Mixture

  2024influential citation
• Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review.

  2024cites this paper
• (R)-ketamine restores anterior insular cortex activity and cognitive deficits in social isolation-reared mice

  2024cites this paper
• Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications

  2024cites this paper
• The N-methyl-d-aspartate receptor hypothesis of ketamine’s antidepressant action: evidence and controversies

  2024cites this paper
• Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.

  2024cites this paper
• Allosteric inhibition of NMDA receptors by low dose ketamine

  2024cites this paper
• Esketamine infusion therapy: A promising alternative in the treatment of chronic endometriosis-associated pain

  2024cites this paper
• A novel NMDA receptor modulator: the antidepressant effect and mechanism of GW043

  2024cites this paper
• Benefits and Risks of Esketamine Nasal Spray Continuation in Treatment-Resistant Depression

  2024cites this paper
• Chirality of New Drug Approvals (2013–2022): Trends and Perspectives

  2024cites this paper
• Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

  2023cites this paper
• Ketamine for Complex Regional Pain Syndrome: A Narrative Review Highlighting Dosing Practices and Treatment Response.

  2023cites this paper
• Application of Ketamine in Pain Management and the Underlying Mechanism

  2023cites this paper
• The clinical toxicology of ketamine

  2023cites this paper
• Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression

  2023cites this paper
• Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist‐induced behavioral disruptions in male and female mice

  2023cites this paper
• Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

  2023influential citation
• Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.

  2023cites this paper
• [Interest and mechanisms of action of ketamine in alcohol addiction- A review of clinical and preclinical studies].

  2023cites this paper
• Esketamine in the treatment of chronic endometriosis-induced pain: a case report

  2023cites this paper
• The effects of esketamine on the intestinal microenvironment and intestinal microbiota in mice

  2023cites this paper
• [Ketamine: a neuropsychotropic drug with an innovative mechanism of action].

  2023cites this paper
• Classics in Chemical Neuroscience: Dextromethorphan (DXM).

  2023cites this paper
• Antidepressants enter cells, organelles, and membranes

  2023cites this paper
• Nebulized and intraperitoneal ketamine have equivalent antidepressant-like effect in the forced swim and tail suspension tests in mice.

  2023cites this paper
• Esketamine accelerates emergence from isoflurane general anaesthesia by activating the paraventricular thalamus glutamatergic neurones in mice.

  2023cites this paper
• Esketamine Inhibits Cocaine-Seeking Behaviour Subsequent to Various Abstinence Conditions in Rats

  2023cites this paper
• Oral ketamine may offer a solution to the ketamine conundrum

  2023cites this paper
• DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness

  2023cites this paper
• The role of NMDARs in the anesthetic and antidepressant effects of ketamine

  2023cites this paper
• A synopsis of multitarget therapeutic effects of anesthetics on depression.

  2023cites this paper
• Mapping metabolite change in the mouse brain after esketamine injection by ambient mass spectrometry imaging and metabolomics

  2023cites this paper
• The antidepressant actions of ketamine and its enantiomers.

  2023cites this paper
• NOTA CLÍNICA A HOPEFUL ALTERNATIVE "THERAPY WITH INTRA-NASAL ESKETAMINE IN A PATIENT WITH RESISTANT DEPRESSION". A CASE REPORT

  2023influential citation
• Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

  2022cites this paper
• Ketamine and its metabolites: Potential as novel treatments for depression.

  2022cites this paper
• Clinical Uses of Ketamine in Children: A Narrative Review

  2022cites this paper
• (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression.

  2022cites this paper
• The molecular pathophysiology of depression and the new therapeutics

  2022cites this paper
• Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence.

  2022cites this paper
• Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

  2022cites this paper
• Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites.

  2022cites this paper
• Identification of a novel norketamine precursor from seized powders: 2-(2-chlorophenyl)-2-nitrocyclohexanone.

  2022cites this paper
• Ketamine, benzoate, and sarcosine for treating depression.

  2022cites this paper
• Midazolam Attenuates Esketamine-Induced Overactive Behaviors in Mice Before the Sedation, but Not During the Recovery

  2022cites this paper
• Is (R)-ketamine a Potential Therapeutic Agent for Treatment-Resistant Depression with Less Detrimental Side Effects? A Review of Molecular Mechanisms Underlying Ketamine and its Enantiomers.

  2022cites this paper
• Arketamine, a new rapid-acting antidepressant: A historical review and future directions.

  2022cites this paper
• Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.

  2022cites this paper
• Efficacy and Tolerability of Oral Compared with Sublingual Ketamine Lozenges as Rescue Analgesics in Adults for Acute Pain: The OSKet Trial

  2021cites this paper
• The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice.

  2021cites this paper
• Ketamine for depression

  2021cites this paper
• Ketamine in Psychiatric Disorders

  2021cites this paper
• Ketamine treatment for refractory anxiety: A systematic review

  2021cites this paper
• Gut microbiota is involved in the antidepressant-like effect of (S)-norketamine in an inflammation model of depression.

  2021cites this paper
• Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

  2021influential citation
• Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model

  2021cites this paper
• Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: A role of TrkB signaling.

  2021cites this paper
• Structural basis of ketamine action on human NMDA receptors

  2021cites this paper
• Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers

  2021cites this paper
• Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti‐depressive drug on the market

  2021cites this paper
• Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

  2021cites this paper
• Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats.

  2020cites this paper
• Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents

  2020cites this paper
• A historical review of antidepressant effects of ketamine and its enantiomers.

  2020cites this paper
• Repurposing of Drugs-The Ketamine Story.

  2020cites this paper
• Evaluation Effect of Tramadol as Premedication on Ketamine in Mice

  2020cites this paper
• Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions

  2020cites this paper
• The neurophysiology of ketamine: an integrative review

  2020cites this paper
• Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

  2020cites this paper
• Ketamine: A tale of two enantiomers

  2020influential citation
• Ketamine Blocks Morphine-Induced Conditioned Place Preference and Anxiety-Like Behaviors in Mice

  2020cites this paper
• Therapeutic Mechanisms of Ketamine.

  2020cites this paper
• Rapid anti‐depressant‐like effects of ketamine and other candidates: Molecular and cellular mechanisms

  2020cites this paper
• Synaptic Modulation in the Effect of Ketamine

  2020cites this paper
• (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.

  2020cites this paper
• Ketamine: From Abused Drug to Rapid-Acting Antidepressant

  2020cites this paper
• Ketamine blocks the correlation between morphine-induced conditioned place preference and anxiety-like behaviors in mice

  2020cites this paper
• Neuronal brain injury after cerebral ischemic stroke is ameliorated after subsequent administration of (R)-ketamine, but not (S)-ketamine.

  2020cites this paper